Survival of induction aumolertinib followed by aumolertinib and concurrent radiotherapy (RT) in unresectable EGFR -mutated stage III NSCLC: Final analysis of the phase III ADVANCE trial and real-world data.
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Nan Bi, Jianyang Wang, Wei Jiang, Xiaolong Fu, Lujun Zhao, Zhe Yang, Dong Qian, Xianglong Chen, Haihua Yang, Hui Wang, Guoyong Shan, Ming Chen, Luhua Wang
Institutions: Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences, Shanghai Jiao Tong University, Shanghai Chest Hospital, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Shandong Provincial Hospital, Shandong First Medical University, Anhui Provincial Hospital, Zhujiang Hospital, Southern Medical University, Wenzhou Medical University, Central South University, Hunan Cancer Hospital, Zhengzhou People's Hospital, Sun Yat-sen University, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410820272